MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

522.25 -7.34 (-1.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,292,907
Open 530.00
Bid (Size) 516.60 (40)
Ask (Size) 535.00 (120)
Prev. Close 529.59
Today's Range 512.77 - 533.67
52wk Range 362.50 - 533.67
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Cash-Heavy Stocks with Promising Prospects
In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for t... 
Via StockStory

Performance

YTD
+15.5%
+15.5%
1 Month
+17.9%
+17.9%
3 Month
+20.9%
+20.9%
6 Month
+11.5%
+11.5%
1 Year
+13.7%
+13.7%

More News

Read More
Which S&P500 stocks are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Vertex to Acquire Crinetics Pharmaceuticals
From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via Business Wire
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗
Via The Motley Fool
News headline image
While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
Via MarketBeat
Topics ETFs
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
Via StockStory
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
Via StockStory
News headline image
If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
Via The Motley Fool
News headline image
3 Market-Beating Stocks Worth Investigating
Via StockStory
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics ETFs
News headline image
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
Via The Motley Fool

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 522.25
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 07/07/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 135.49B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 135B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story